Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
News
Recent Posts
- Dazucorilant shows significant survival benefit in Phase 2 ALS trial
- Seeking to harness ‘real momentum’ is goal of this year’s ALS Awareness Month
- How I stimulate my mind while caring for my husband with ALS
- Developer gets OK to expand first-in-human trial of ALS therapy to Europe
- Out-of-pocket ALS costs create heavy financial burden for French families